PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV

Poster Psoriasis
P 35
Long-term improvement in patient-reported outcomes after transition from
methotrexate to ustekinumab in moderate to severe psoriasis: TRANSIT Week
52 results
K. Reich 1
L. Puig 2
T. Luger 3
J. Lambert 4
S. Chimenti 5
G. Girolomoni 6
J.-F. Nicolas 7
K. Kragballe 8
S Mistry 9
P Bergmans 10
G. Thompson 9
J. Barker 11
C. Paul 12
1 Georg-August University, Hamburg, Germany
2 Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona,
Spain
3 University of Munster, Munster, Germany
4 Ghent University Hospital, Ghent, Belgium
5 University of Rome, Rome, Italy
6 University of Verona, Verona, Italy
7 University of Lyon, Lyon, France
8 Arhus University, Arhus, Denmark
9 Janssen-Cilag Ltd, High Wycombe, UK
10 Janssen-Cilag BV, Tilburg, Netherlands
11 St John's Institute of Dermatology, King's College, London, UK
12 Larrey Hospital, Paul Sabatier University, Toulouse, France
Introduction & Objectives: The Phase IV TRANSIT study compared outcomes in
psoriasis patients with inadequate response to methotrexate (MTX), following
immediate or gradual transition to ustekinumab. We describe Week 52 quality of life
outcomes. Materials & Methods In this 52-week open-label, parallel group trial, 490
patients with moderate to severe plaque psoriasis despite treatment with MTX
(10-25mg/week for greater than or equal to 8 weeks) were randomised 1:1 to
ustekinumab with either a) immediate cessation of MTX (Arm 1), or b) 4 weeks' overlap
with decreasing MTX dose (Arm 2). Ustekinumab was administered according to label:
45mg in patients less than or equal to 100kg or 90mg if >100kg. Patients less than or
equal to 100kg not achieving adequate response (Psoriasis Area Severity Index decrease
from baseline greater than or equal to 75% [PASI 75]) at Week 28 or Week 40 were dose
87